How similar is your antibody to clinical-stage therapeutics?
(*)NB: ABodyBuilder-ML has been deprecated as ABodyBuilder2 is now our main tool for antibody structure modelling. This will have an effect on computed TAP scores and thresholds for flagging. To stay up-to-date with any new changes to our tools, follow our Twitter account.
For a full description of the TAP metrics, please refer to: Raybould MIJ, et al. Five Computational Developability Guidelines for Therapeutic Antibody Profiling. PNAS. (2019)
Please cite our paper "Five Computational Developability Guidelines for Therapeutic Antibody Profiling" if making use of these datasets.
NB: 31tstJanuary 2023, the TAP protocol was updated to use Fv models generated by ABodyBuilder2, our new version of ABodyBuilder that is part of ImmuneBuilder, a set of deep-learning models for structure prediction of immune proteins, including antibodies, nanobodies, and T-cell receptors (TCRs). TAP scores and therapeutic thresholds have changed accordingly. Please avoid interpreting the results from previous TAP runs against these new thresholds; instead resubmit your sequences to TAP to ensure the modelling methodology is consistent
|Property||Amber Region (31st January 2023)||Red Region (31st January 2023)|
|Total CDR Length (L)||37 ≤ L ≤ 42||L < 37|
|55 ≤ L ≤ 63||L > 63|
|Patches of Surface Hydrophobicity (PSH)||95.72 ≤ PSH ≤ 110.71||PSH < 95.72|
|168.82 ≤ PSH ≤ 207.09||PSH > 207.09|
|Patches of Positive Charge (PPC)||1.34 ≤ PPC ≤ 4.27||PPC > 4.27|
|Patches of Negative Charge (PNC)||1.95 ≤ PNC ≤ 4.43||PNC > 4.43|
|Structural Fv Charge Symmetry Parameter (SFvCSP)||-30.60 ≤ SFvCSP ≤ -6.0||SFvCSP < -30.60|
Please visit Thera-SAbDab to access our latest CST sequence data.